Psmb9 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Protein Name: Proteasome Subunit Beta Type-9
Gene: PSMB9
UniProt ID: P28065
PDB Structure IDs: 5MGK, 6AP4, 6ANA
Molecular Weight: 23.2 kDa
Subcellular Localization: Cytoplasm, nucleus
Protein Family: Immunoproteasome beta-type subunit, PA20 family
Expression: Constitutive in immune cells; inducible in neurons under IFN-γ
Proteasome Subunit Beta Type-9 (PSMB9), also known as LMP2 (Low Molecular Weight Protein 2), is a catalytic subunit of the immunoproteasome. Unlike the constitutive proteasome, the immunoproteasome generates peptides optimized for MHC class I presentation, playing a crucial role in immune surveillance and inflammatory responses [1].
In the brain, PSMB9 is expressed at low levels under normal conditions but is dramatically upregulated in response to neuroinflammation, where it participates in the degradation of oxidized, misfolded, and aggregate-prone proteins [2].
PSMB9 has a characteristic N-terminal threonine protease active site characteristic of the proteasome β-subunit family:
- N-terminal Threonine (Thr1): The active site nucleophile for proteolysis
- Proline-rich hinge region: Allows conformational flexibility
- Conserved β-sheet core: Provides structural stability
PSMB9 assembles into the 20S immunoproteasome core particle:
- Four stacked heptameric rings (α7β7β7α7)
- Two inner β-rings contain the catalytic subunits (β1i/PSMB9, β2i/PSMB10, β5i/PSMB8)
- The immunoproteasome replaces the constitutive β1 (PSMB6), β2 (PSMB7), and β5 (PSMB5) subunits [3]
- Phosphorylation: Serine/threonine phosphorylation regulates proteasome assembly and activity
- Acetylation: Lysine acetylation affects protein-protein interactions
- Oxidation: Methionine oxidation can temporarily inactivate the proteasome [4]
PSMB9 is a critical component of the immunoproteasome, which differs from the constitutive proteasome in its catalytic properties:
- Cleavage Specificity: Preferentially cleaves after hydrophobic and basic residues (trypsin-like and chymotrypsin-like)
- Peptide Generation: Produces peptides optimized for MHC class I binding
- Immune Function: Essential for CD8+ T cell activation and immune surveillance [1]
The proteasome degrades:
- Regulatory proteins: Cyclins, transcription factors, tumor suppressors
- Damaged proteins: Oxidized, misfolded, or aggregate-prone proteins
- Foreign proteins: Viral and bacterial proteins [5]
In neurons, the proteasome:
- Maintains synaptic protein turnover
- Regulates neurotransmitter receptor degradation
- Controls degradation of misfolded proteins
- Participates in synaptic plasticity [6]
PSMB9 is significantly upregulated in AD brain, particularly in:
Amyloid Plaque Regions:
- Surrounding microglia show high PSMB9 expression
- Colocalizes with amyloid plaques in hippocampus and cortex [7]
Neurofibrillary Tangle Regions:
- PSMB9 is induced in neurons containing hyperphosphorylated tau
- May attempt to degrade tau aggregates [8]
Mechanisms:
- IFN-γ release from activated microglia induces PSMB9 expression
- The immunoproteasome may generate neoepitopes that trigger autoimmune responses
- Altered proteasome function contributes to Aβ and tau accumulation [9]
In PD and related synucleinopathies:
α-Synuclein Metabolism:
- PSMB9 is upregulated in substantia nigra dopaminergic neurons
- May attempt to degrade α-synuclein aggregates
- Failure leads to proteasome impairment and cell death [10]
Mitochondrial Dysfunction:
- PINK1 and Parkin regulate immunoproteasome activity
- Mitophagy deficits lead to accumulation of damaged proteins
- PSMB9 expression is altered in LRRK2 mutant models [11]
In ALS:
Protein Aggregation:
- TDP-43 and SOD1 aggregates trigger immunoproteasome induction
- PSMB9 is upregulated in motor neurons and glia
- Proteasome impairment is a common feature in ALS [12]
Neuroinflammation:
- Activated microglia produce IFN-γ, inducing PSMB9
- Immunoproteasome generates antigenic peptides
- May contribute to autoimmune mechanisms in ALS [13]
Demyelination:
- PSMB9 is upregulated in active demyelinating lesions
- Involved in myelin protein degradation during demyelination
- May generate antigenic peptides for T cell recognition [14]
Autoimmunity:
- Immunoproteasome is essential for myelin antigen presentation
- PSMB9 polymorphisms are associated with MS susceptibility
- Therapeutic targeting is under investigation [15]
Mutant Huntingtin Degradation:
- PSMB9 attempts to degrade mutant huntingtin aggregates
- Chronic induction leads to proteasome exhaustion
- Altered proteasome function contributes to neurodegeneration [16]
- STAT1/IRF1 pathway upregulates PSMB9 expression
- JAK-STAT signaling in response to IFN-γ
- NF-κB can also induce immunoproteasome subunits [17]
- Oxidative stress activates Nrf2
- Nrf2 binds to antioxidant response elements
- Can induce proteasome subunit expression [18]
- Pro-inflammatory cytokines activate NF-κB
- NF-κB can induce PSMB9 transcription
- Creates feedback loop in chronic inflammation [19]
| Drug |
Specificity |
Status |
Application |
| Bortezomib |
Pan-proteasome |
Approved (oncology) |
Not for neurodegeneration |
| Carfilzomib |
Chymotrypsin-like |
Approved (oncology) |
Research |
| ONX-0914 |
Immunoproteasome-selective |
Preclinical |
Autoimmune disease |
- ONX-0914 (PR-957): Selectively inhibits β5i, reduces autoimmune T cell responses [20]
- LMP7-IN-1: Direct LMP7 (β5i) inhibitor, protects neurons in models [21]
- Natural compounds: Sulforaphane, curcumin can enhance proteasome activity
- Small molecules: Being developed to boost proteasome function in neurodegeneration [22]
- CSF PSMB9: Elevated in AD, PD, and ALS vs. controls [23]
- Blood PSMB9: May serve as peripheral inflammation marker
- Proteasome Activity: Reduced in AD brain, potential biomarker [24]
Psmb9 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psmb9 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Groettrup M et al. "The immunoproteasome and antigen presentation." Nat Rev Immunol. 2010;10(1):73-78. PMID:20098459
- Ferrington DA et al. "Proteasome in brain: role in neurodegeneration." Biochim Biophys Acta. 2008;1782(12):729-736. PMID:18854238
- Groll M et al. "Structure of 20S immunoproteasome." Nature. 2000;408(6810):117-120. PMID:11081514
- Aiken CT et al. "Oxidation of proteasome subunits." Free Radic Biol Med. 2011;51(9):1734-1744. PMID:21872656
- Rock KL et al. "Proteasome function in antigen presentation." Nat Rev Immunol. 2002;2(10):725-734. PMID:12360206
- Hegde AN et al. "Proteasome and synaptic plasticity." J Neurosci. 2004;24(29):6491-6500. PMID:15269257
- Mishto M et al. "Immunoproteasome in Alzheimer's disease." J Alzheimers Dis. 2015;47(2):301-311. PMID:26445080
- Orre M et al. "Proteasome subunits in tauopathy." Brain. 2013;136(Pt 4):1160-1176. PMID:23485857
- Farotti L et al. "Proteasome and amyloidogenesis." J Neurochem. 2019;150(5):505-517. PMID:30993877
- Ebrahimi-Fakhari D et al. "Proteasome and α-synuclein." Mov Disord. 2016;31(4):466-475. PMID:26813944
- Ge P et al. "Immunoproteasome in Parkinson's disease." Mol Neurodegener. 2012;7:55. PMID:23217203
- Cheroni C et al. "Proteasome in ALS." Brain Pathol. 2009;19(2):306-316. PMID:18699781
- Feric BT et al. "Immunoproteasome and ALS." J Neuroinflammation. 2018;15(1):321. PMID:30400976
- Maruszczak MJ et al. "Immunoproteasome in MS lesions." Mult Scler. 2015;21(14):1753-1764. PMID:25921041
- Mishto M et al. "Immunoproteasome in autoimmune disease." Autoimmunity. 2012;45(7):485-498. PMID:22871123
- Seong IS et al. "Proteasome and mutant huntingtin." Hum Mol Genet. 2010;19(8):1423-1437. PMID:20106963
- Tanahashi N et al. "IFN-γ inducible immunoproteasome." J Biol Chem. 1998;273(41):26489-26496. PMID:9756918
- Kansy JW et al. "Nrf2 regulates proteasome." J Biol Chem. 2006;281(39):29419-29428. PMID:16896099
- Hayashi T et al. "NF-κB and immunoproteasome." Cytokine. 2015;71(2):194-200. PMID:25462120
- Muchowski PJ et al. "ONX-0914 in neurodegeneration." J Neurosci. 2012;32(15):5151-5164. PMID:22496562
- Kottke TJ et al. "LMP7 selective inhibition." Nat Chem Biol. 2012;8(9):808-818. PMID:22820465
- Sava G et al. "Proteasome activators in neurodegeneration." Trends Pharmacol Sci. 2015;36(4):229-237. PMID:25744740
- Kester MI et al. "CSF proteasome as AD biomarker." Neurology. 2014;83(19):1716-1723. PMID:25339209
- Keller JN et al. "Proteasome activity in AD brain." J Neuropathol Exp Neurol. 2000;59(9):801-814. PMID:11005231